Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: A systematic review and meta-analysis

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 119, Issue 7, 2012, Pages 778-787

  Kleinrouweler, C E ^a   Wiegerinck, M M J ^a   Ris Stalpers, C ^a   Bossuyt, P M M ^a   Van Der Post, J A M ^a   Von Dadelszen, P ^b   Mol, B W J ^a   Pajkrt, E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomarkers; placental growth factor; pre eclampsia; soluble endoglin; soluble fms like tyrosine kinase 1; vascular endothelial growth factor

Indexed keywords

ENDOGLIN; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

EMBASE; FALSE POSITIVE RESULT; GESTATIONAL AGE; HUMAN; MEDLINE; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ANTIGENS, CD; BIOLOGICAL MARKERS; FEMALE; HUMANS; ODDS RATIO; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84861094112     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2012.03311.x     Document Type: Review

References (61)

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R,. Pre-eclampsia. Lancet 2010; 376: 631-44.
2. Duley L, Henderson-Smart DJ, Meher S, King JF,. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;: CD004659.
3. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA,. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-8. (Pubitemid 46782996)
4. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al., Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-14.
5. James JL, Whitley GS, Cartwright JE,. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol 2010; 221: 363-78.
6. Gu Y, Lewis DF, Wang Y,. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93: 260-6.
7. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al., Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-58. (Pubitemid 36278583)
8. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, et al., Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555-63. (Pubitemid 37452769)
9. Zhu X, Wu S, Dahut WL, Parikh CR,. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-93. (Pubitemid 46178407)
10. Roberts JM, Hubel CA,. The two stage model of preeclampsia: variations on the theme. Placenta 2009; 30 (Suppl.): 32-7.
11. Huppertz B,. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008; 51: 970-5. (Pubitemid 351398986)
12. Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, et al., Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008; 12: iii-iv, 1-270.
13. Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M,. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007; 109: 168-80. (Pubitemid 46035522)
14. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al., Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12. (Pubitemid 30214957)
15. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J,. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006; 6: 9.
16. Brown MA, Lindheimer MD, de SM, Van AA, Moutquin JM,. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV. (Pubitemid 32672922)
17. Review Manager (RevMan) [Computer program] Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
18. Deeks JJ,. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157-62. (Pubitemid 32678396)
19. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM,. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-35. (Pubitemid 37386338)
20. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A,. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.
21. Akolekar R, Zaragoza E, Poon LCY, Pepes S, Nicolaides KH,. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 732-9.
22. Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, et al., Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol 2010; 203: 383-8.
23. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV,. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199: 266.
24. Bersinger NA, Odegard RA,. Serum levels of macrophage colony stimulating, vascular endothelial, and placenta growth factor in relation to later clinical onset of pre-eclampsia and a small-for-gestational age birth. Am J Reprod Immunol 2005; 54: 77-83. (Pubitemid 41087070)
25. Bills VL, Varet J, Millar A, Harper SJ, Soothill PW, Bates DO,. Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin Sci (Lond) 2009; 116: 265-72.
26. Bosio PM, Wheeler T, Anthony F, Conroy R, O'Herlihy C, McKenna P,. Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am J Obstet Gynecol 2001; 184: 146-52. (Pubitemid 32141657)
27. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, et al., Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18. (Pubitemid 40515938)
28. Crispi F, Llurba E, Dominguez C, Martin-Gallan P, Cabero L, Gratacos E,. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008; 31: 303-9.
29. Diab AE, El-Behery MM, Ebrahiem MA, Shehata AE,. Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2008; 102: 146-51.
30. Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Goncalves LF, et al., Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007; 196: 326.e1-13.
31. Koga K, Osuga Y, Tajima T, Hirota Y, Igarashi T, Fujii T, et al., Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 2010; 94: 305-8.
32. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, et al., A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009; 22: 1021-38.
33. Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM,. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008; 111: 1403-9.
34. Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, et al., The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 2010; 117: 456-62.
35. Madazli R, Kuseyrioglu B, Uzun H, Uludag S, Ocak V,. Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2005; 89: 251-7. (Pubitemid 40779295)
36. Park CW, Park JS, Shim SS, Jun JK, Yoon BH, Romero R,. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 2005; 193: 984-9. (Pubitemid 41285481)
37. Parra M, Rodrigo R, Barja P, Bosco C, Fernandez V, Munoz H, et al., Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 2005; 193: 1486-91. (Pubitemid 41395121)
38. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK,. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101: 1266-74. (Pubitemid 36694354)
39. Powers RW, Jeyabalan A, Clifton RG, Van DP, Hauth JC, Klebanoff MA, et al., Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS ONE 2010; 5: e13263.
40. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, et al., Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137-42. (Pubitemid 46986022)
41. Robinson CJ, Johnson DD,. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol 2007; 197: 174-5.
42. Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH,. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol 2008; 32: 871-6.
43. Schmidt M, Dogan C, Birdir C, Kuhn U, Gellhaus A, Kimmig R, et al., Placental growth factor: a predictive marker for preeclampsia? Gynakol Geburtshilfliche Rundsch 2009; 49: 94-9.
44. Shokry M, Bedaiwy MA, Fathalla MM, Alsemary A, Elwakil S, Murphy A,. Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Acta Obstet Gynecol Scand 2010; 89: 143-6.
45. Sibai BM, Koch MA, Freire S, Pinto e Silva JL, Rudge MV, Martins-Costa S, et al., Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 2008; 199: 268-9.
46. Stepan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R,. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008; 198: 175-6.
47. Stepan H, Unversucht A, Wessel N, Faber R,. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49: 818-24. (Pubitemid 351664216)
48. Su YN, Lee CN, Cheng WF, Shau WY, Chow SN, Hsieh FJ,. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001; 97: 898-904. (Pubitemid 32522485)
49. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al., First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770-5. (Pubitemid 38269892)
50. Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, et al., Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension 2004; 43: 988-92. (Pubitemid 38579903)
51. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS,. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267-72. (Pubitemid 32434285)
52. Tjoa ML, van Vugt JM, Mulders MA, Schutgens RB, Oudejans CB, van WI,. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98: 600-7. (Pubitemid 32907454)
53. Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH,. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia. BJOG 2010; 117: 1384-9.
54. Yu J, Shixia CZ, Wu Y, Duan T,. Inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2011; 37: 528-33.
55. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al., Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-83. (Pubitemid 38364626)
56. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al., Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005. (Pubitemid 44343543)
57. National Collaborating Centre for Women's and Children's Health. Antenatal Care: Routine Care for the Healthy Pregnant Woman [Clinical guideline]. London: National Institute for Health and Clinical Excellence, 2008.
58. Nicolaides KH,. A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment. Prenat Diagn 2011; 31: 3-6.
59. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et al., Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 2010; 56: 741-9.
60. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, et al., Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 2011; 342: d1875.
61. Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH,. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn 2010; 30: 216-23.